XNAS 05 May, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael Daughton | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 10,572 | 68,064 (0%) | 0% | 0 | Common Stock | |
| Merideth Wilson | Financial Health GM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 5,206 | 12,042 (0%) | 0% | 0 | Common Stock | |
| David B. Harse | General Manager Patient Care | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 5,079 | 21,091 (0%) | 0% | 0 | Common Stock | |
| Vita MacIntyre | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 909 | 2,687 (0%) | 0% | 0 | Common Stock | |
| Vinay Bassi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 12,698 | 50,499 (0%) | 0% | 0 | Common Stock | |
| Kevin Plessner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 2,598 | 14,610 (0%) | 0% | 0 | Common Stock | |
| Christopher L. Fowler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2026 | 19,683 | 136,772 (0%) | 0% | 0 | Common Stock | |
| Vita MacIntyre | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.07 per share. | 27 Mar 2026 | 187 | 1,778 (0%) | 0% | 14.1 | 2,631 | Common Stock |
| David B. Harse | General Manager Patient Care | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.59 per share. | 13 Mar 2026 | 1,098 | 16,012 (0%) | 0% | 17.6 | 19,314 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 2,213 | 122,998 (0%) | 0% | 17.3 | 38,307 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.59 per share. | 13 Mar 2026 | 5,909 | 117,089 (0%) | 0% | 17.6 | 103,939 | Common Stock |
| David A. Dye | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 1,285 | 86,428 (0%) | 0% | 17.3 | 22,243 | Common Stock |
| David A. Dye | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.59 per share. | 13 Mar 2026 | 2,793 | 83,635 (0%) | 0% | 17.6 | 49,129 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.59 per share. | 13 Mar 2026 | 825 | 12,012 (0%) | 0% | 17.6 | 14,512 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 340 | 12,837 (0%) | 0% | 17.3 | 5,885 | Common Stock |
| Vinay Bassi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 1,758 | 41,766 (0%) | 0% | 17.3 | 30,431 | Common Stock |
| Vinay Bassi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.59 per share. | 13 Mar 2026 | 3,965 | 37,801 (0%) | 0% | 17.6 | 69,744 | Common Stock |
| Vita MacIntyre | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 125 | 1,965 (0%) | 0% | 17.3 | 2,164 | Common Stock |
| David B. Harse | General Manager Patient Care | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 571 | 17,110 (0%) | 0% | 17.3 | 9,884 | Common Stock |
| Merideth Wilson | Financial Health GM | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.31 per share. | 13 Mar 2026 | 604 | 6,836 (0%) | 0% | 17.3 | 10,455 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.47 per share. | 09 Mar 2026 | 280 | 13,177 (0%) | 0% | 18.5 | 5,172 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.47 per share. | 09 Mar 2026 | 2,093 | 125,211 (0%) | 0% | 18.5 | 38,658 | Common Stock |
| David B. Harse | General Manager Patient Care | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.47 per share. | 09 Mar 2026 | 377 | 17,681 (0%) | 0% | 18.5 | 6,963 | Common Stock |
| Michael Daughton | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 20.46 per share. | 11 Nov 2025 | 17,500 | 57,492 (0%) | 0% | 20.5 | 358,050 | Common Stock |
| Michael Daughton | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 20.15 per share. | 11 Nov 2025 | 2,500 | 39,992 (0%) | 0% | 20.2 | 50,375 | Common Stock |
| Michael Daughton | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 19.39 per share. | 11 Nov 2025 | 15,479 | 22,971 (0%) | 0% | 19.4 | 300,138 | Common Stock |
| Michael Daughton | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 19.95 per share. | 11 Nov 2025 | 10,167 | 33,138 (0%) | 0% | 20.0 | 202,832 | Common Stock |
| Michael Daughton | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 20.16 per share. | 11 Nov 2025 | 4,354 | 37,492 (0%) | 0% | 20.2 | 87,777 | Common Stock |
| Michael Daughton | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 7,492 | 7,492 (0%) | 0% | 0 | Common Stock | |
| Vita MacIntyre | Controller | Sale of securities on an exchange or to another person at price $ 24.94 per share. | 20 May 2025 | 335 | 2,090 (0%) | 0% | 24.9 | 8,355 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 16 May 2025 | 6,000 | 131,090 (0%) | 0% | 25.1 | 150,300 | Common Stock |
| Vita MacIntyre | Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.53 per share. | 27 Mar 2025 | 188 | 2,425 (0%) | 0% | 28.5 | 5,364 | Common Stock |
| David B. Harse | General Manager Patient Care | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.10 per share. | 17 Mar 2025 | 1,098 | 19,802 (0%) | 0% | 28.1 | 30,854 | Common Stock |
| Vinay Bassi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.10 per share. | 17 Mar 2025 | 3,965 | 43,524 (0%) | 0% | 28.1 | 111,417 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.10 per share. | 17 Mar 2025 | 798 | 13,457 (0%) | 0% | 28.1 | 22,424 | Common Stock |
| Dawn M. Severance | Chief Sales Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.10 per share. | 17 Mar 2025 | 1,122 | 30,595 (0%) | 0% | 28.1 | 31,528 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.10 per share. | 17 Mar 2025 | 5,849 | 137,090 (0%) | 0% | 28.1 | 164,357 | Common Stock |
| David B. Harse | General Manager Patient Care | Sale of securities on an exchange or to another person at price $ 27.40 per share. | 14 Mar 2025 | 1,744 | 18,058 (0%) | 0% | 27.4 | 47,786 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.02 per share. | 14 Mar 2025 | 5,100 | 142,939 (0%) | 0% | 27.0 | 137,802 | Common Stock |
| Jerry Canada G. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 4,376 (0%) | 0% | 0 | Common Stock | |
| Merideth Wilson | Financial Health GM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 7,440 | 7,440 (0%) | 0% | 0 | Common Stock | |
| Merideth Wilson | Financial Health GM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 5,981 | 5,981 (0%) | 0% | 0 | Common Stock | |
| David Harse B. | General Manager Patient Care | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 5,835 | 20,900 (0%) | 0% | 0 | Common Stock | |
| Andris Upitis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 4,376 (0%) | 0% | 0 | Common Stock | |
| Vinay Bassi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 14,588 | 47,489 (0%) | 0% | 0 | Common Stock | |
| Vita MacIntyre | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 1,044 | 2,613 (0%) | 0% | 0 | Common Stock | |
| Christopher L. Fowler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 22,611 | 148,039 (1%) | 0% | 0 | Common Stock | |
| Christopher T. Hjelm | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 31,591 (0%) | 0% | 0 | Common Stock | |
| Glenn P. Tobin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 50,687 (0%) | 0% | 0 | Common Stock | |
| David A. Dye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 98,645 (0%) | 0% | 0 | Common Stock | |
| Mark V. Anquillare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 21,554 (0%) | 0% | 0 | Common Stock | |
| Regina M. Benjamin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 4,376 | 38,687 (0%) | 0% | 0 | Common Stock | |
| Dawn M. Severance | Chief Sales Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 5,055 | 31,717 (0%) | 0% | 0 | Common Stock | |
| Kevin Plessner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 2,985 | 14,255 (0%) | 0% | 0 | Common Stock | |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.30 per share. | 07 Mar 2025 | 197 | 11,590 (0%) | 0% | 28.3 | 5,576 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.31 per share. | 07 Mar 2025 | 320 | 11,270 (0%) | 0% | 28.3 | 9,058 | Common Stock |
| Dawn M. Severance | Chief Sales Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.31 per share. | 07 Mar 2025 | 386 | 26,662 (0%) | 0% | 28.3 | 10,926 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.30 per share. | 07 Mar 2025 | 2,092 | 125,428 (0%) | 0% | 28.3 | 59,214 | Common Stock |
| Dawn M. Severance | Chief Sales Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.30 per share. | 07 Mar 2025 | 328 | 27,048 (0%) | 0% | 28.3 | 9,284 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.30 per share. | 07 Mar 2025 | 791 | 127,520 (0%) | 0% | 28.3 | 22,389 | Common Stock |
| David A. Dye | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.47 per share. | 31 Dec 2024 | 1,416 | 87,713 (0%) | 0% | 18.5 | 26,154 | Common Stock |
| David A. Dye | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Dec 2024 | 9,516 | 89,129 (0%) | 0% | 0 | Common Stock | |
| Mark V. Anquillare | Director | Purchase of securities on an exchange or from another person at price $ 16.81 per share. | 25 Nov 2024 | 2,500 | 17,178 (0%) | 0% | 16.8 | 42,025 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.48 per share. | 01 Jul 2024 | 2,278 | 127,304 (0%) | 0% | 23.5 | 53,487 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.57 per share. | 01 Jul 2024 | 1,508 | 129,582 (0%) | 0% | 10.6 | 15,940 | Common Stock |
| Vita MacIntyre | Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 1,569 | 1,569 (0%) | 0% | 0 | Common Stock | |
| Regina M. Benjamin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,964 | 34,311 (0%) | 0% | 0 | Common Stock | |
| Christopher L. Fowler | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 49,850 | 128,311 (0%) | 0% | 0 | Common Stock | |
| Christopher T. Hjelm | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,964 | 27,215 (0%) | 0% | 0 | Common Stock | |
| Glenn P. Tobin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,964 | 46,311 (0%) | 0% | 0 | Common Stock | |
| David A. Dye | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 28,548 | 94,269 (0%) | 0% | 0 | Common Stock | |
| Mark V. Anquillare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,964 | 14,678 (0%) | 0% | 0 | Common Stock | |
| Denise W. Warren | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,964 | 34,311 (0%) | 0% | 0 | Common Stock | |
| Dawn M. Severance | Chief Sales Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 13,819 | 27,376 (0%) | 0% | 0 | Common Stock | |
| Kevin Plessner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 7,238 | 11,787 (0%) | 0% | 0 | Common Stock | |
| Lance Park | VP Finance & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 9,970 | 13,052 (0%) | 0% | 0 | Common Stock | |
| Vinay Bassi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 32,901 | 32,901 (0%) | 0% | 0 | Common Stock | |
| Wes Cronkite | Chief Technology & Innovation | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 20,128 | 40,717 (0%) | 0% | 0 | Common Stock | |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 2,862 | 79,332 (0%) | 0% | 8.1 | 23,096 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.98 per share. | 07 Mar 2024 | 871 | 78,461 (0%) | 0% | 9.0 | 7,822 | Common Stock |
| David A. Dye | Director, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.98 per share. | 07 Mar 2024 | 865 | 65,721 (0%) | 0% | 9.0 | 7,768 | Common Stock |
| David A. Dye | Director, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 2,154 | 66,586 (0%) | 0% | 8.1 | 17,383 | Common Stock |
| Dawn M. Severance | SVP of TruBridge, Sales | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.98 per share. | 07 Mar 2024 | 439 | 13,557 (0%) | 0% | 9.0 | 3,942 | Common Stock |
| Dawn M. Severance | SVP of TruBridge, Sales | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 869 | 13,996 (0%) | 0% | 8.1 | 7,013 | Common Stock |
| Wes Cronkite | Chief Technology & Innovation | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 1,456 | 20,589 (0%) | 0% | 8.1 | 11,750 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.98 per share. | 07 Mar 2024 | 217 | 4,549 (0%) | 0% | 9.0 | 1,949 | Common Stock |
| Kevin Plessner | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 517 | 4,766 (0%) | 0% | 8.1 | 4,172 | Common Stock |
| Lance Park | VP Finance & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.07 per share. | 07 Mar 2024 | 339 | 3,082 (0%) | 0% | 8.1 | 2,736 | Common Stock |
| Glenn P. Tobin | Director | Purchase of securities on an exchange or from another person at price $ 8.04 per share. | 07 Mar 2024 | 10,500 | 34,347 (0%) | 0% | 8.0 | 84,420 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 11.33 per share. | 14 Nov 2023 | 9 | 9 (0%) | 0% | 11.3 | 102 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 14 Nov 2023 | 5 | 14 (0%) | 0% | 11 | 55 | Common Stock |
| Christopher L. Fowler | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 14 Nov 2023 | 2 | 16 (0%) | 0% | 11 | 22 | Common Stock |
| Mark V. Anquillare | Director | Grant, award, or other acquisition of securities at price $ 25.79 per share. | 28 Jul 2023 | 2,714 | 2,714 (0%) | 0% | 25.8 | 69,994 | Common Stock |